Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome.

@article{Clav2011RandomisedCT,
  title={Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome.},
  author={Pere Clav{\'e} and Monica Acalovschi and John K. Triantafillidis and Yu. P. Uspensky and Cemalettin Kalayci and Vikram Shee and Jan Tack},
  journal={Alimentary pharmacology & therapeutics},
  year={2011},
  volume={34 4},
  pages={
          432-42
        }
}
BACKGROUND Otilonium bromide (OB) is a spasmolytic agent that blocks L-Type Calcium channels in human colonic smooth muscle. AIM To study the efficacy of OB in symptom control in irritable bowel syndrome (IBS). METHODS A total of 356 patients (46.16±19years, 71% female) with IBS participated in a double-blind, randomised, parallel placebo-controlled phase IV study. OB (40mg t.d.s.) or placebo was administered for 15weeks, and follow-up was extended 10 additional weeks. RESULTS Otilonium… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 32 CITATIONS

IBS and the role of otilonium bromide

  • International Journal of Colorectal Disease
  • 2012
VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Is otilonium bromide globally effective in irritable bowel syndrome?

  • Alimentary pharmacology & therapeutics
  • 2011
VIEW 2 EXCERPTS
CITES METHODS
HIGHLY INFLUENCED

Clinical Practice Guidelines for Irritable Bowel Syndrome in Korea, 2017 Revised Edition

  • Journal of neurogastroenterology and motility
  • 2018
VIEW 1 EXCERPT
CITES METHODS